Dr Philip Mease of Swedish Medical Center in Seattle discusses highlights in psoriatic arthritis (PsA) from the American College of Rheumatology Convergence 2022 annual meeting.
Dr Mease starts with new phase 2 data on deucravacitinib, a highly specific TYK2 inhibitor that has been approved for patients with plaque psoriasis. In this study, deucravacitinib achieved states of low disease activity or remission over a 52-week period in patients with PsA.
Next, Dr Mease presents a late-breaking phase 2 study of bimekizumab, an IL-17A and IL-17F inhibitor. Bimekizumab treated all domains of PsA and had inhibitory effects on structural damage progression over 52 weeks.
He next discusses a study investigating the IL-23 inhibitor guselkumab in patients with the axial component of PsA, a condition for which a widely accepted definition has been elusive. The study randomized patients to detection of axial disease either by imaging or machine learning; guselkumab showed clinically meaningful improvements in both groups, underscoring its efficacy in the axial-specific domain regardless of the means of detection.
Dr Mease then discusses results with the novel molecule izokibep, which targets IL-17A. The study showed promising results, particularly in enthesitis.
Finally, Dr Mease discusses a study examining how fibromyalgia concomitant with PsA may affect the assessment of disease activity.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Psoriatic Arthritis Highlights From ACR 2022 - Medscape - Dec 05, 2022.
Comments